News | Mammography | June 30, 2017

Nation’s largest independent provider of breast screening services recognized for improving technology, leading to fewer recalls and higher retention rates

Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50

June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the Dallas Business Journal. Rankings of the publication’s third annual research project were based on both private and public companies with revenue between $25 million and $750 million. Fifty-three companies that met the annual revenue requirements in the 2017 Middle Market 50 were awarded at the 2017 Middle Market 50 Awards Dinner at the Ritz Carlton in Dallas.

Headquartered in Addison, Texas, Solis currently operates 37 centers across six major markets – North Texas; Houston, Texas; Phoenix, Ariz.; Columbus, Ohio; Greensboro, N.C.; and, through its acquisition of Washington Radiology, the D.C. metropolitan area. The company operates both wholly-owned centers and multiple joint ventures with hospital partners. Solis Mammography (including Washington Radiology) serves more than 600,000 patients each year with highly-specialized breast imaging services including screening and diagnostic mammography (2-D and 3-D), computer-aided detection, breast ultrasound, stereotactic biopsy and ultrasound-guided biopsy.

Over the past three years, the company has committed $16 million to upgrade all of its centers with 3-D mammography (also known as digital breast tomosynthesis), lowering unnecessary recalls by 37 percent and increasing cancer detection by 54 percent. Taken together, these changes have earned the company a 76 percent annual retention rate with returning patients, far higher than the national average of 53 percent.

Under the leadership of James Polfreman, the company has more than doubled its footprint since he joined the company in 2011, increasing revenue by more than 250 percent and creating a fivefold increase in bottom line, earnings before interest, tax, depreciation and amortization (EBITDA).

For more information: www.solismammo.com


Related Content

News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Women's Health

Dec. 1, 2025 — ScreenPoint Medical has completed a commercial agreement making its Transpara breast-imaging AI portfolio ...

Time December 03, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
Subscribe Now